Ftse Mib
33.474,83
0,18%
DAX
19.905,79
1,41%
S&P 500
6.047,68
0,82%
NASDAQ
19.378,99
0,84%
Bitcoin
96.359,44
-0,93%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Cellectis Nom Eo 05 (ALCLS) Cellectis Nom Eo 05 (ALCLS) Notizie

ALCLS

Cellectis Nom Eo 05 (ALCLS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:ALCLS
DataOraFonteTitoloSimboloCompagnia
05/11/202422:30GlobeNewswire Inc.Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingEU:ALCLSCellectis Nom Eo 05
04/11/202422:30GlobeNewswire Inc.Cellectis Provides Business Updates and Financial Results for Third Quarter 2024EU:ALCLSCellectis Nom Eo 05
30/10/202421:30GlobeNewswire Inc.Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024EU:ALCLSCellectis Nom Eo 05
22/10/202408:00GlobeNewswire Inc.Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressEU:ALCLSCellectis Nom Eo 05
03/09/202422:30GlobeNewswire Inc.Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetyEU:ALCLSCellectis Nom Eo 05
26/08/202422:30GlobeNewswire Inc.Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid TumorsEU:ALCLSCellectis Nom Eo 05
07/08/202408:00GlobeNewswire Inc.Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical OfficerEU:ALCLSCellectis Nom Eo 05
06/08/202422:30GlobeNewswire Inc.Cellectis Provides Financial Results for the Second Quarter 2024EU:ALCLSCellectis Nom Eo 05
01/08/202422:30GlobeNewswire Inc.FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL TreatmentEU:ALCLSCellectis Nom Eo 05
25/07/202422:30GlobeNewswire Inc.FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) TreatmentEU:ALCLSCellectis Nom Eo 05
05/07/202422:30GlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
05/07/202422:30GlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
28/06/202422:30GlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
28/06/202422:30GlobeNewswire Inc.Résultats de l’Assemblée Générale Mixte de Cellectis du 28 juin 2024EU:ALCLSCellectis Nom Eo 05
20/06/202422:30GlobeNewswire Inc.Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingEU:ALCLSCellectis Nom Eo 05
20/06/202422:30GlobeNewswire Inc.Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editorsEU:ALCLSCellectis Nom Eo 05
12/06/202422:30GlobeNewswire Inc.Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature CommunicationsEU:ALCLSCellectis Nom Eo 05
12/06/202422:30GlobeNewswire Inc.Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsEU:ALCLSCellectis Nom Eo 05
04/06/202422:30GlobeNewswire Inc.Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaEU:ALCLSCellectis Nom Eo 05
04/06/202422:30GlobeNewswire Inc.Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguëEU:ALCLSCellectis Nom Eo 05
29/05/202422:30GlobeNewswire Inc.L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024EU:ALCLSCellectis Nom Eo 05
29/05/202422:30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
28/05/202422:30GlobeNewswire Inc.Cellectis publie ses résultats financiers du premier trimestre 2024EU:ALCLSCellectis Nom Eo 05
28/05/202422:30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024EU:ALCLSCellectis Nom Eo 05
27/05/202422:30GlobeNewswire Inc.Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024EU:ALCLSCellectis Nom Eo 05
27/05/202422:30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
06/05/202408:00GlobeNewswire Inc.Cellectis annonce la réalisation de l’investissement additionnel d’AstraZenecaEU:ALCLSCellectis Nom Eo 05
06/05/202408:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
02/05/202422:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
02/05/202422:30GlobeNewswire Inc.Cellectis nomme Arthur Stril directeur financier par intérimEU:ALCLSCellectis Nom Eo 05
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:ALCLS

La tua Cronologia

USOTC
TTNMF
Titanium Transportation (QX)
BIT
SBUX
Starbucks
TSX
CPX.PR.C
Capital Power
LSE
NSI
New Star Investment
BIT
TUR
ETF
USOTC
OROVF
Orient Overseas (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network